These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30488489)

  • 1. Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma.
    Li X; Seebacher NA; Xiao T; Hornicek FJ; Duan Z
    J Orthop Res; 2019 Feb; 37(2):510-521. PubMed ID: 30488489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma.
    Walker RL; Hornicek FJ; Duan Z
    Biochem Pharmacol; 2024 Aug; 226():116342. PubMed ID: 38848777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
    Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
    Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.
    Minami Y; Kohsaka S; Tsuda M; Yachi K; Hatori N; Tanino M; Kimura T; Nishihara H; Minami A; Iwasaki N; Tanaka S
    Cancer Sci; 2014 Sep; 105(9):1152-9. PubMed ID: 24989082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.
    Li X; Seebacher NA; Garbutt C; Ma H; Gao P; Xiao T; Hornicek FJ; Duan Z
    Cell Death Dis; 2018 May; 9(5):446. PubMed ID: 29670090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of SS18-SSX1 expression by small interfering RNA inhibits growth and induces apoptosis in human synovial sarcoma cell line HS-SY-II in vitro.
    Peng C; Guo W; Yang Y; Zhao H
    Eur J Cancer Prev; 2008 Oct; 17(5):392-8. PubMed ID: 18714179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
    Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
    Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.
    Ma H; Seebacher NA; Hornicek FJ; Duan Z
    EBioMedicine; 2019 Jan; 39():182-193. PubMed ID: 30579871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
    Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
    J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.
    Wang J; Dean DC; Hornicek FJ; Shi H; Duan Z
    FASEB J; 2019 May; 33(5):5990-6000. PubMed ID: 30726104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SS18-SSX drives CREB activation in synovial sarcoma.
    Cyra M; Schulte M; Berthold R; Heinst L; Jansen EP; Grünewald I; Elges S; Larsson O; Schliemann C; Steinestel K; Hafner S; Simmet T; Wardelmann E; Kailayangiri S; Rossig C; Isfort I; Trautmann M; Hartmann W
    Cell Oncol (Dordr); 2022 Jun; 45(3):399-413. PubMed ID: 35556229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.
    Zöllner SK; Rössig C; Toretsky JA
    Cancer Metastasis Rev; 2015 Sep; 34(3):417-28. PubMed ID: 26277104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SRC signaling is crucial in the growth of synovial sarcoma cells.
    Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
    Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of CDK7-dependent transcriptional addiction is a potential therapeutic target in synovial sarcoma.
    Li X; Dean DC; Yuan J; Temple TH; Trent JC; Rosenberg AE; Yu S; Hornicek FJ; Duan Z
    Biomed Pharmacother; 2022 May; 149():112888. PubMed ID: 35367753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.
    Brien GL; Remillard D; Shi J; Hemming ML; Chabon J; Wynne K; Dillon ET; Cagney G; Van Mierlo G; Baltissen MP; Vermeulen M; Qi J; Fröhling S; Gray NS; Bradner JE; Vakoc CR; Armstrong SA
    Elife; 2018 Nov; 7():. PubMed ID: 30431433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth.
    Törnkvist M; Natalishvili N; Xie Y; Girnita A; D'Arcy P; Brodin B; Axelson M; Girnita L
    Biochem Biophys Res Commun; 2008 Apr; 368(3):793-800. PubMed ID: 18267106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
    Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
    Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation.
    Allander SV; Illei PB; Chen Y; Antonescu CR; Bittner M; Ladanyi M; Meltzer PS
    Am J Pathol; 2002 Nov; 161(5):1587-95. PubMed ID: 12414507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma.
    Friedrichs N; Trautmann M; Endl E; Sievers E; Kindler D; Wurst P; Czerwitzki J; Steiner S; Renner M; Penzel R; Koch A; Larsson O; Tanaka S; Kawai A; Schirmacher P; Mechtersheimer G; Wardelmann E; Buettner R; Hartmann W
    Int J Cancer; 2011 Oct; 129(7):1564-75. PubMed ID: 21128248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic utility of reduced immunohistochemical expression of SMARCB1 in synovial sarcomas: a validation study.
    Ito J; Asano N; Kawai A; Yoshida A
    Hum Pathol; 2016 Jan; 47(1):32-7. PubMed ID: 26520417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.